These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients. Böhme A, Hoelzer D. Mycoses; 1996; 39(11-12):419-26. PubMed ID: 9144997 [Abstract] [Full Text] [Related]
24. Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK. Flynn TN, Kelsey SM, Hazel DL, Guest JF. Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):543-50. PubMed ID: 10662479 [Abstract] [Full Text] [Related]
25. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Wolff SN, Fay J, Stevens D, Herzig RH, Pohlman B, Bolwell B, Lynch J, Ericson S, Freytes CO, LeMaistre F, Collins R, Pineiro L, Greer J, Stein R, Goodman SA, Dummer S. Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206 [Abstract] [Full Text] [Related]
26. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J, Wilson W. Antimicrob Agents Chemother; 1998 Sep; 42(9):2391-8. PubMed ID: 9736569 [Abstract] [Full Text] [Related]
27. [Analysis of the use of liposomal amphotericin B]. González Martínez M, Mariño Martínez C, Baldominos Utrilla G, Fernández Martínez MN. Rev Iberoam Micol; 2014 Sep; 31(2):109-13. PubMed ID: 23711815 [Abstract] [Full Text] [Related]
30. A randomized comparative trial evaluating the safety and efficacy of liposomal amphotericin B (Fungisome) versus conventional amphotericin B in the empirical treatment of febrile neutropenia in India. Jadhav MP, Shinde VM, Chandrakala S, Jijina F, Menon H, Arora B, Kurkure PA, Parikh PM, Kshirsagar NA. Indian J Cancer; 2012 Sep; 49(1):107-13. PubMed ID: 22842177 [Abstract] [Full Text] [Related]
33. Conventional vs. liposomal amphotericin B in immunosuppressed children. Zoubek A, Emminger W, Emminger-Schmidmeier W, Peters C, Pracher E, Grois N, Gadner H. Pediatr Hematol Oncol; 1992 Sep; 9(2):187-90. PubMed ID: 1524992 [Abstract] [Full Text] [Related]
34. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Cagnoni PJ. J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():81-6. PubMed ID: 11801587 [Abstract] [Full Text] [Related]
35. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection. Bodhe PV, Kotwani RN, Kirodian BG, Kshirsagar NA, Pandya SK. J Assoc Physicians India; 2002 May; 50(5):662-70. PubMed ID: 12186120 [Abstract] [Full Text] [Related]
36. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children. Ringdén O, Tollemar J. Mycoses; 1993 May; 36(5-6):187-92. PubMed ID: 8264715 [Abstract] [Full Text] [Related]